{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:23:50Z","timestamp":1790490230972,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>HLA disparity is traditionally measured at the antigen or allele level, and its impact on haploidentical hematopoietic cell transplantation (haplo-HCT) with high-dose posttransplant cyclophosphamide (PTCy) is unclear. To the best of our knowledge, the relationship between HLA eplet\u2013derived epitope mismatch (EM) and clinical outcome has not been examined in haplo-HCT. We retrospectively analyzed 148 patients who received a peripheral blood, T-cell\u2013replete haplo-HCT with PTCy at a single center. HLA EM was quantified using an HLAMatchmaker-based method and was stratified by class and vector. The primary outcome was incidence of relapse. The total number of mismatched epitopes (MEs) per patient-donor pair in our patient population ranged from 0 to 51 (median, 24) in the graft-versus-host (GVH) direction and 0 to 47 (median, 24) in the host-versus-graft (HVG) direction. Higher HLA class II EM in the GVH direction was associated with a significantly reduced risk of relapse (adjusted hazard ratio [HR], 0.952 per ME; P = .002) and improved relapse-free survival (adjusted HR, 0.974 per ME; P = .020). Higher HLA class II EM in the HVG direction was associated with longer time to neutrophil (adjusted HR, 0.974 per ME; P = .013) and platelet (adjusted HR, 0.961 per ME; P = .001) engraftment. In peripheral blood haplo-HCT patients, increased HLA EM was associated with a protective effect on the risk of relapse in the GVH direction but a negative effect on time to count recovery in the HVG direction. HLA EM based on the HLA Matchmaker represents a novel strategy to predict clinical outcome in haplo-HCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018025437","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T16:55:15Z","timestamp":1545152115000},"page":"3590-3601","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-2091","authenticated-orcid":false,"given":"Joseph","family":"Rimando","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation and Leukemia Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Slade","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation and Leukemia Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation and Leukemia Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation and Leukemia Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1425-1623","authenticated-orcid":false,"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-4736","authenticated-orcid":false,"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Transplantation, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"12","key":"2020021109105880400_B1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","article-title":"A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome","volume":"9","author":"Fung","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"2020021109105880400_B2","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"2020021109105880400_B3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/asheducation-2008.1.412","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available","volume":"2008","author":"Appelbaum","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2020021109105880400_B4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021109105880400_B5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109105880400_B6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109105880400_B7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"issue":"10","key":"2020021109105880400_B8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020021109105880400_B9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/bmt.2014.62","article-title":"T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor","volume":"49","author":"Bashey","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020021109105880400_B10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/bmt.2014.108","article-title":"Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes","volume":"49","author":"Bhamidipati","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020021109105880400_B11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","article-title":"Comparison of outcomes of hematopoietic cell transplants from t-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020021109105880400_B12","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020021109105880400_B13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/bmt.2016.283","article-title":"Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation","volume":"52","author":"Ma","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020021109105880400_B14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020021109105880400_B15","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bbmt.2016.05.010","article-title":"Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021109105880400_B16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","article-title":"T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia","volume":"23","author":"How","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020021109105880400_B17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bbmt.2017.06.019","article-title":"Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome","volume":"23","author":"Slade","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021109105880400_B18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109105880400_B19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020021109105880400_B20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/bmt.2016.117","article-title":"HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020021109105880400_B21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2017.10.002","volume":"24","author":"Raiola","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021109105880400_B22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020021109105880400_B23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021109105880400_B24","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515","article-title":"Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient","volume":"92","author":"Petersdorf","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2020021109105880400_B25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2003-02-0430","article-title":"Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000)","volume":"102","author":"Kanda","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2020021109105880400_B26","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood-2007-02-072405","article-title":"High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism","volume":"110","author":"Kawase","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2020021109105880400_B27","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2020021109105880400_B28","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2014-05-576041","article-title":"Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation","volume":"124","author":"Pidala","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020021109105880400_B29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.humimm.2006.08.001","article-title":"A structurally based approach to determine HLA compatibility at the humoral immune level","volume":"67","author":"Duquesnoy","year":"2006","journal-title":"Hum Immunol"},{"issue":"1","key":"2020021109105880400_B30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.humimm.2006.10.003","article-title":"HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP","volume":"68","author":"Duquesnoy","year":"2007","journal-title":"Hum Immunol"},{"issue":"12","key":"2020021109105880400_B31","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1111\/ajt.12478","article-title":"Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes","volume":"13","author":"Wiebe","year":"2013","journal-title":"Am J Transplant"},{"issue":"10","key":"2020021109105880400_B32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.humimm.2013.06.025","article-title":"Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry","volume":"74","author":"Gragert","year":"2013","journal-title":"Hum Immunol"},{"issue":"36","key":"2020021109105880400_B33","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109105880400_B34","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020021109105880400_B35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2020021109105880400_B36","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2020021109105880400_B37","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2020021109105880400_B38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2020021109105880400_B39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0198-8859(91)90115-P","article-title":"T cell can recognize the allospecificities formed by the substitution of amino acids associated with HLA-Bw4\/Bw6 public epitopes","volume":"32","author":"Hiraiwa","year":"1991","journal-title":"Hum Immunol"},{"issue":"3","key":"2020021109105880400_B40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00375373","article-title":"Allospecific T cell recognition of HLA-A2 antigens: evidence for group-specific and subgroup-specific epitopes","volume":"21","author":"Wallace","year":"1985","journal-title":"Immunogenetics"},{"issue":"13","key":"2020021109105880400_B41","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1073\/pnas.87.13.5213","article-title":"Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule","volume":"87","author":"Elliott","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2020021109105880400_B42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0198-8859(86)90064-9","article-title":"Fine specificity of human HLA-B7-specific cytotoxic T-lymphocyte clones. I. Identification of HLA-B7 subtypes and histotopes of the HLA-B7 cross-reacting group","volume":"16","author":"van Seventer","year":"1986","journal-title":"Hum Immunol"},{"issue":"1-2","key":"2020021109105880400_B43","first-page":"27","article-title":"Alloreactive cytotoxic T-lymphocyte-defined HLA-B7 subtypes differ in peptide antigen presentation","volume":"43","author":"Smith","year":"1996","journal-title":"Immunogenetics"},{"issue":"6","key":"2020021109105880400_B44","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1365-2141.2003.04212.x","article-title":"Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia","volume":"120","author":"Vollmer","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021109105880400_B45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1349-7006.2006.00356.x","article-title":"Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts","volume":"98","author":"Masuda","year":"2007","journal-title":"Cancer Sci"},{"issue":"3","key":"2020021109105880400_B46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0198-8859(01)00381-0","article-title":"Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon","volume":"63","author":"Brouwer","year":"2002","journal-title":"Hum Immunol"},{"issue":"9","key":"2020021109105880400_B47","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2008.07.001","article-title":"HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors","volume":"14","author":"Duquesnoy","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021109105880400_B48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020021109105880400_B49","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1500140","article-title":"High HLA-DP expression and graft-versus-host disease","volume":"373","author":"Petersdorf","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/24\/3590\/1555075\/advances025437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/24\/3590\/1555075\/advances025437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:47:55Z","timestamp":1581414475000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/24\/3590\/15991\/HLA-epitope-mismatch-in-haploidentical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":49,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018025437","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]}}}